title: Management of prostate cancer in China: a multicenter report of 6 institutions.
abstract: OBJECTIVE
  In China the incidence of prostate cancer (PCa) is low and sparse data are available regarding its management. We analyzed the management of PCa at 6 Chinese urological institutions.
  
  
  METHODS
  A retrospective analysis was performed of 431 consecutive patients treated for PCa at 6 Chinese institutions, including 5 in the divisions of Shanghai and 1 in the province of Chongqing, between January 2000 and December 2004. Tumor characteristics, therapeutic options and patient outcomes were recorded.
  
  
  RESULTS
  At diagnosis median patient age was 72 years and median prostate specific antigen was 46.1 ng/ml. Most PCa cases were revealed by urinary symptoms (75.9%) or bone pain (12.8%). PCa was palpable on digital rectal examination in 74% of cases. At least 44 patients (10.2%) had metastases to lymph nodes at diagnosis and 112 (26%) had bone metastases. A total of 236 patients underwent bilateral orchiectomy and 100 received medical hormone therapy, which in 75% consisted of antiandrogen alone. At a median followup of 16.8 months 60% of these patients experienced biological recurrence. Radical prostatectomy was performed in 24 patients as monotherapy or in combination with bilateral orchiectomy. No patient with clinically localized PCa experienced biological recurrence after radical prostatectomy.
  
  
  CONCLUSIONS
  The management of PCa in China differs from that in Western countries. To date surgical castration represents standard treatment. Screening detection of PCa could help detect earlier stage tumors and improve the outcome in patients.
authors.affiliation: Department of Urology, Cochin Hospital, Paris, France. michael.peyromaure@cch.ap-hop-paris.fr
authors.forename: Michaël
authors.initials: M
authors.lastname: Peyromaure
authors.forename: Bernard
authors.initials: B
authors.lastname: Debré
authors.forename: Kaili
authors.initials: K
authors.lastname: Mao
authors.forename: Guoqiang
authors.initials: G
authors.lastname: Zhang
authors.forename: Yiran
authors.initials: Y
authors.lastname: Wang
authors.forename: Zhongquan
authors.initials: Z
authors.lastname: Sun
authors.forename: Danfeng
authors.initials: D
authors.lastname: Xu
authors.forename: Jun
authors.initials: J
authors.lastname: Jiang
authors.forename: Yinghao
authors.initials: Y
authors.lastname: Sun
mesh_terms: D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D002681:China / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000473:pathology; D009367:Neoplasm Staging; D009919:Orchiectomy / Q000379:methods; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen